Visual acuity outcomes in ranibizumab‐treated neovascular age‐related macular degeneration; stratified by baseline vision

摘要: Background:  Ranibizumab (Lucentis, Novartis, Basel, Switzerland) is currently indicated for use in neovascular age-related macular degeneration (NVAMD). This study assessed the real-life outcomes based on baseline visual acuity when treated with intravitreal ranibizumab a three + pro re nata (PRN) dosing schedule NVAMD. Design:  retrospective chart-review was conducted at King's College Hospital. The patients were stratified into groups Early treatment diabetic retinopathy (ETDRS) letters: 27 poor (24–34 letters), 33 intermediate (35–54 letters) and good (≥=55 letters). Methods:  All received PRN of injections (0.5 mg per 0.05 mL) changes thickness optical coherence tomography (OCT) all completed 12-month follow up. Main Outcome Measures:  mean change 12 months groups. Results:  Mean gain ETDRS letters +14.00 (P < 0.0001), +7.10 (P = 0.012) +2.85 (P = 0.19), number 5.30, 6.12 5.70 poor, vision group, respectively, over 12- month follow-up period. Conclusions:  Poor predictor maximum acuity. However, eyes better (55 had final